Compare Expeditors International of Wshngtn Inc (EXPD) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Medpace Holdings Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $193.74 (market cap $25.18B), while Medpace Holdings Inc trades at $602 (market cap $16.82B). The key difference: Expeditors International of Wshngtn Inc is the larger of the two by market cap, and Expeditors International of Wshngtn Inc pays a 0.84% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and Medpace Holdings Inc for 14 Days on average.
| EXPD | MEDP | |
|---|---|---|
Market Cap | $25.18B | $16.82B |
Volume | 1,003,557 | 223,093 |
Sector | Industrials | Health |
52-Week High | $194.12 | $630.19 |
52-Week Low | $113.13 | $393.42 |
Typical Hold Time | 43 Days | 14 Days |
Enterprise Value | $24.72B | $16.44B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $190.85, down 0.5% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.03 surpassing the $1.69 estimate. Revenue for 2025 reached $11.07 billion, with a net income margin of 7.63% and robust ROE of 42.6%. Recent news highlights efficiency initiatives and resilient airfreight demand as positive catalysts.
The outlook is mixed; solid profitability and earnings momentum support upside, but the stock trades above the consensus price target of $179.43, with analysts predominantly neutral (63.64% Hold). Key risks include freight market volatility and execution challenges. Institutional activity shows mixed signals, with some firms increasing stakes while others reduce positions.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
